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ABSTRACT
Objective: The aim of this case series was to assess the effectiveness and tol-
erability of aripiprazole in Korean children and adolescents with early-onset schizo-
phrenia spectrum (EOSS) disorder.
Methods: The medical records of aripiprazole-treated patients with EOSS were 
retrospectively reviewed. Changes in illness severity were measured using the Clinical 
Global Impression–Severity of Illness (CGI-S) and Clinical Global Impression–
Improvement (CGI-I) scales.
Results: Data from 22 children and adolescents were included (12 girls, 
10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole 
was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treat-
ment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly 
from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes 
in chart-extracted CGI-I scores, significantly greater improvement was associated 
with negative symptoms compared with positive symptoms (U = 25.5; P = 0.028; 
r = –0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients 
(22.7%) and treatment-emergent adverse events in 3 patients (13.6%).
Conclusion: The results from this small study suggest that aripiprazole was 
moderately effective in reducing psychotic symptoms in these Korean children and 
adolescents with EOSS. (Curr Ther Res Clin Exp. 2009;70:173–183) © 2009 Excerpta 
Medica Inc.
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INTRODUCTION
Early-onset schizophrenia spectrum (EOSS) disorder is a chronic disabling disease 
with poor clinical and functional outcomes.1 Therefore, the identification of an effective 
and well-tolerated treatment for EOSS is essential. Mounting concerns over the 
tolerability of first-generation antipsychotics have encouraged the use of second-
generation antipsychotics in children and adolescents with EOSS.2 Based on re-
sults from studies in adults, the risks for weight gain and metabolic dysregulation 
with second-generation antipsychotics (eg, clozapine, risperidone, olanzapine, 
quetiapine) have become important issues.3 Results from a retrospective study 
examining the US Food and Drug Administration database by comparing differ-
ent age groups suggested that the risks for weight gain and hyperprolactinemia 
with olanzapine might be higher in children than in adults.4,5 Because treatment 
with atypical antipsychotics is at times continued throughout the various stages 
of development in children and adolescents, we cannot rule out the possibility 
that adverse events that have not been reported in adult patients may exist in 
children.
Aripiprazole is an antipsychotic with partial agonism at several G-protein–coupled 
receptors (eg, D2 and 5-HT1A) and functional antagonism at several serotonin recep-
tors (eg, 5-HT2A, 5-HT2B, 5-HT6).
6 These characteristics may have resulted in de-
creased extrapyramidal symptom (EPS) liability and minimal prolactin elevation 
compared with other antipsychotics, such as risperidone.7 The more favorable meta-
bolic adverse-events profile of aripiprazole has been attributed to its low to moderate 
occupancy of histamine H1 and α1- and α2-adrenergic receptors.8 The efficacy and 
tolerability of aripiprazole in children and adolescents have been investigated in 
several open-label studies9–13 and a randomized, double-blind, placebo-controlled 
study.14 Cautious recommendations are being made about the use of aripiprazole in 
pediatric patients with treatment-refractory psychosis.15
Many questions regarding the appropriate dosage and the tolerability of aripipra-
zole in Asian children and adolescents remain unanswered.16,17 Aripiprazole, which is 
metabolized by human cytochrome P450 (CYP) isoforms CYP3A4 and CYP2D6,18 
has been reported to have high inter- and intraindividual variability in the serum 
concentrations of both aripiprazole and dehydroaripiprazole, an active metabolite of 
aripiprazole.19 Ethnic differences in genetic polymorphisms of CYP2D620 that influ-
ence the serum concentration of aripiprazole and dehydroaripiprazole have been re-
ported.21 Based on a literature search (MEDLINE; key terms: ethnic, difference, and 
aripiprazole; years: 1999–2009), no study has directly compared interethnic differences 
in the dosage and adverse events of aripiprazole. However, studies comparing ethnic 
differences in the metabolism of haloperidol22 and risperidone,23 which are also me-
tabolized by CYP2D6,24 suggest that ethnicity significantly affects the metabolism of 
these antipsychotics.
Randomized, double-blind, placebo-controlled studies of aripiprazole14,25 have 
provided valuable information, but no method has been developed to identify the 
long-term effects of medication on children and adolescents through short-term con-
trolled studies.26 Therefore, sharing long-term clinical experiences through retrospec-
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tive review of clinical practice is important in the pharmacologic treatment of chil-
dren and adolescents. We report the results from a case series of clinical experience 
with aripiprazole in the treatment of children and adolescents with EOSS.
PATIENTS AND METHODS
Data from April 2004 (when aripiprazole was introduced) to December 2007 were 
collected from the inpatient and outpatient electronic health records at the Child and 
Adolescent Psychiatric Unit, Seoul National University Children’s Hospital, Seoul, 
Republic of Korea. Data were included from children and adolescents aged 6 to 
18 years who were diagnosed with schizophrenia or schizoaffective disorder according 
to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition27 based on a clinical interview with a parent and the child conducted by a 
treating psychiatrist. Diagnosis was confirmed by another board-certified child and 
adolescent psychiatrist (Y.K.) through review of psychiatric records from children who 
had been prescribed aripiprazole. The chart review and the waiver of informed consent 
were approved by the institutional review board at Seoul National University.
Efficacy
Chart-extracted Clinical Global Impression–Severity of Illness (CGI-S) scores were 
used to assess the severity of psychiatric symptoms from baseline through the end of 
the aripiprazole trial (scale: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly 
ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most 
extremely ill). Clinical Global Impression–Improvement (CGI-I) scores were used to 
evaluate target symptom improvement at the end of the trial (1 = very much im-
proved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally 
worse; 6 = much worse; and 7 = very much worse).28 Two independent board-certified 
psychiatrists with good inter-rater reliability (κ = 0.84) conducted the CGIs on all 
of the patients; the psychiatrists were blinded to each other’s ratings. A third psy-
chiatrist (Y.K.) compared the 2 ratings. If there was disagreement between the CGI 
ratings made by the 2 initial raters, a consensus was reached through discussion. 
Patients were considered to be treatment responders if they were assigned an end point 
CGI-I rating of 1 or 2. 
Tolerability
Tolerability of aripiprazole was assessed retrospectively by recording adverse events 
based on those documented in the charts.
Statistical Analysis
Nonparametric analysis was carried out after Kolmogorov-Smirnov tests were per-
formed to assess the normality of the data. The Wilcoxon signed rank test was per-
formed to detect differences between baseline and end point CGI-S scores. Clinical 
correlates of the response and nonresponse groups were compared using the Fisher 
exact test for categoric data (eg, sex) and the Mann-Whitney U test for continuous 
data (eg, CGI-S ratings, medication dosage, treatment duration). The CGI-I scores of 
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the patients with positive target symptoms were compared with those of the patients 
with negative target symptoms using the Mann-Whitney U test. All tests were 
2-tailed, and P < 0.05 was considered statistically significant. All statistical analyses 
were performed using SPSS version 13.0 (SPSS Inc., Chicago, Illinois). 
RESULTS
A total of 226 children and adolescents who had been prescribed aripiprazole were 
identified, 22 of whom were included in the analyses and ranged in age from 6.5 to 
16.8 years (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). Seventeen patients 
(77.3%) were diagnosed with schizophrenia; 5 (22.7%), with schizoaffective disorder. 
The mean age at symptom onset was 11.8 (2.3) years. Ten patients (45.5%) report- 
ed a family history of schizophrenia or other psychotic illness. The mean dosage 
of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d; 
0.43 [0.18] mg/kg/d), and the mean duration of treatment was 207.9 (237.5) days 
(range, 21–838 days; <30 days, 7 patients; 30–<100 days, 3; 100–<200 days, 4; 
200–<400 days, 5; ≥400 days, 3). A total of 21 patients (95.5%) were receiving con-
current medication (olanzapine, 7 patients; risperidone, 6; clozapine, 5; fluoxetine, 3; 
topiramate, 2; valproate, 2; bupropion, 1; fluvoxamine, 1; lithium, 1; methylpheni-
date, 1; quetiapine, 1; and venlafaxine, 1). Six patients (27.3%) were receiving mul-
tiple concomitant medications during the aripiprazole trial.
Of the 22 patients, 20 (91.0%) were treated with aripiprazole after a trial of at least 
1 other atypical antipsychotic. A majority of patients (17 [77.3%]) started treatment 
with aripiprazole without discontinuing their prior antipsychotics to augment the 
insufficient effect of the prior treatment (14 [82.4%]) or because an increase in 
the dosage of the prior antipsychotics was not possible due to intolerable adverse 
events, including weight gain (4 patients [23.5%]), electroencephalographic changes 
(2 [11.8%]), and EPSs (1 [5.9%]).
Mean (SD) CGI-S score decreased significantly from baseline to end point (5.7 [0.7] 
to 4.3 [1.4]; Wilcoxon signed rank test: t = 2.5; P < 0.001; effect size = –0.54). Fif-
teen patients (68.2%) had scores of ≥4 (moderately ill to extremely ill) on the CGI-S 
at the treatment end point.
As for the assessment of target symptoms, the mean CGI-I score at study end was 
2.6 (1.1) (between much improved and minimally improved). Based on CGI-I scores, 
3 patients (13.6%) were considered very much improved; 10 (45.5%), much im-
proved; 3 (13.6%), minimally improved; 5 (22.7%), no change; and 1 (4.5%), mini-
mally worse.
A family history of schizophrenia or other psychotic disorder was significantly as-
sociated with clinical response to aripiprazole (P = 0.027), as was the duration of 
treatment (U = 20.5; P = 0.009; r = –0.54) (Table). The children diagnosed with 
schizophrenia were found to have a higher response rate after using aripiprazole (12/17 
[70.6%]) compared with children diagnosed with schizoaffective disorder (1/5 
[20.0%]). Sex, parental educational level, age at onset of symptoms, age at initiation 
of aripiprazole treatment, CGI-S score at baseline, and the maintenance dosage were 
not associated with response to aripiprazole.
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Eighteen patients (81.8%) had target symptoms that were classified as positive (for-
mal thought disorder, bizarre behavior, hallucination, and delusion) and 9 (40.9%) had 
symptoms classified as negative (anhedonia-asociality, avolition-apathy, affective flatten-
ing, and alogia). A significantly greater improvement was found in clinical response to 
aripiprazole in the negative symptoms than the positive symptoms (U = 25.5; P = 
0.028; r = –0.47). The negative symptoms were found to have a more favorable response 
(7/8 [87.5%]) than the positive symptoms (6/14 [42.9%]) (P = 0.04) (Figure).
Table.  Baseline demographic and clinical characteristics of the study patients with early-
onset schizophrenia spectrum disorder classified as nonresponders and responders 
based on the Clinical Global Impression–Improvement scale (N = 22).
 Responders Nonresponders Test of 
Characteristic (n = 13) (n = 9) Significance
Sex, no. (%)   Fisher exact test, 
   P = 0.099
  Male 8 (38.5) 2 (77.8)
  Female 5 (61.5) 7 (22.2) 
Age at initiation of    U = 45.5; P = 0.38; 
aripiprazole, y   r = –0.19
  Mean (SD) 14.4 (1.8) 13.4 (3.1) 
  Range 10.7–16.8 6.5–16.7
Age at onset of   U = 45.5; P = 0.38; 
symptoms, y   r = –0.19
  Mean (SD) 12.2 (1.9) 11.1 (2.8)
  Range 9–15 5–14
Parental education, 15.2 (2.9) 14.6 (2.9) U = 50.5; P = 0.57; 
mean (SD), y   r = –0.12
No. (%) of patients with 3 (13.6) 7 (31.8) Fisher exact test, 
family history of    P = 0.027 
psychotic disorders 
Diagnosis, no. (%)   Fisher exact test, 
   P = 0.067
  Schizophrenia 12 (92.3) 5 (55.6)
  Schizoaffective disorder 1 (7.7) 4 (44.4)
Baseline CGI-S score*  5.6 (0.8) 5.9 (0.6) U = 47.5; P = 0.40; 
   r = –0.18
Duration of aripiprazole   U = 20; P = 0.009; 
treatment, d   r = –0.54
  Mean (SD) 272.8 (249.6) 114.2 (194.6) 
  Range 28–838 21–596 
Aripiprazole dosage, 19.4 (10.7) 20.3 (7.8) U = 54.0; P = 0.761; 
mean (SD), mg/d   r = –0.06
CGI-S = Clinical Global Impression–Severity of Illness.
* Scale: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 
6 = severely ill; and 7 = among the most extremely ill. 
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Fourteen of the 22 patients (63.6%) were receiving aripiprazole treatment at the 
time of data collection. Aripiprazole treatment was discontinued due to insufficient 
effect in 5 patients (22.7%) and treatment-emergent adverse effects in 3 patients 
(13.6%) (akathisia [2] and motor EPSs [1]). The mean (SD) duration of aripiprazole 
use until discontinuation due to adverse events was 103.3 (84.6) days. The adverse 
events reported by the patients included motor EPSs (6 [27.3%] patients), insomnia 
(4 [18.2%]), akathisia (2 [9.1%]), nausea (2 [9.1%]), sedation (2 [9.1%]), tics 
(2 [9.1%]), blurred vision (1 [4.5%]), constipation (1 [4.5%]), dizziness (1 [4.5%]), 
and dry mouth (1 [4.5%]).
There were no significant differences between the patients who experienced adverse 
events and those who did not in terms of age at initiation of aripiprazole treatment 
(14.0 [2.8] vs 13.9 [2.0] years), age at onset of symptoms (11.8 [2.7] vs 11.8 [1.8] years), 
mean aripiprazole dosage (22.5 [10.1] vs 15.0 [5.8] mg/d), or duration of aripiprazole 
use (242.2 [276.5] vs 147.5 [143.7] days).
The weight and body mass index (BMI) at baseline and during aripiprazole treat-
ment were available in 17 and 11 children, respectively. At the onset of aripiprazole 
treatment, the mean (SD) weight was 55.5 (15.1) kg (median, 56.5 kg [range, 28– 
85 kg]) and the mean (SD) BMI was 21.4 (3.3) kg/m2 (median, 21.8 kg/m2 [range, 
16.1–27.4 kg/m2]). Mean weight and BMI at the last point of data collection were 
57.5 (15.4) kg (median, 58.9 kg [range, 28–83 kg]) and 21.5 (3.3) kg/m2 (median, 
22.0 kg/m2 [range, 16.4–25.6 kg/m2]). An increase in mean weight of 2 kg was ob-
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Figure.  The symptom-specific clinical response to aripiprazole in 22 children and adoles-
cents with early-onset schizophrenia spectrum disorder assessed using the Clinical 
Global Impression–Improvement (CGI-I) scale. The negative symptoms (7 respond-
ers and 1 nonresponder; 87.5% response) were more likely to respond to aripipra-
zole than the positive symptoms (6 responders and 8 nonresponders; 42.9% re-
sponse). There was a statistically significant difference in the CGI-I mean scores of 
positive and negative symptoms to aripiprazole (U = 25.5; P = 0.028; r = –0.47).
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served, but the difference was not statistically significant. The difference in mean BMI 
before and after aripiprazole treatment was not statistically significant.
The blood glucose and serum cholesterol concentrations at baseline and during 
aripiprazole treatment were available in 10 and 12 children, respectively. The mean 
(SD) blood glucose concentrations at baseline and at the last data collection were 
93.4 (13.6) mg/dL (median, 91 mg/dL [range, 79–127 mg/dL]) and 85 (4.9) mg/dL 
(median, 85 mg/dL [range, 78–92 mg/dL]), respectively. Serum cholesterol concentra-
tions were 174 (25.5) mg/dL (median, 174.5 mg/dL [range, 128–211 mg/dL]) and 
167.4 (40.3) mg/dL (median, 160 mg/dL [range, 124–246 mg/dL]), respectively. De- 
creases in concentrations of blood glucose and cholesterol were 8.4 and 6.6 mg/dL, 
respectively; neither decrease was statistically significant. No significant correlations 
with age at the initiation of aripiprazole treatment, age at onset of illness, aripiprazole 
dose by weight, duration of aripiprazole treatment, or metabolic changes (weight, 
BMI, blood glucose concentration, and serum cholesterol concentration) were 
observed.
DISCUSSION
The results from the present case series suggested that aripiprazole may be moder-
ately effective for the treatment of EOSS in children and adolescents. Results from 
symptom-specific assessment of treatment response using the CGI-I suggested that 
aripiprazole might be more effective in reducing negative symptoms. A multicenter, 
randomized controlled trial of aripiprazole in adolescents with schizophrenia consisting 
of 3 treatment groups (10 and 30 mg and placebo) reported a statistically significant 
reduction in Positive and Negative Syndrome Scale29 total score compared with pla-
cebo.14 Results from a case series of 3 adults with schizophrenia suggested that aug-
menting clozapine treatment with aripiprazole was effective for negative symptoms.30 
However, the results must be interpreted carefully, and future blinded controlled tri-
als are needed to validate the findings from the present study.
Twenty-one patients (95.5%) in the present study were receiving concurrent medi-
cations, and 6 patients (27.3%) were receiving ≥2 concurrent medications during the 
aripiprazole trial. The high percentage of patients receiving combination therapy in 
the present study might mean that these cases were refractory to treatment. One ret-
rospective chart review of studies in 248 patients reported that 82% of 28 children 
prescribed second-generation antipsychotics and 100% of 12 children prescribed first-
generation antipsychotics were receiving multiple medications,16 suggesting that the 
degree of polypharmacy was much higher in patients prescribed antipsychotics than 
in those prescribed other classes of psychotropic drugs. However, because the effec-
tiveness and tolerability of polypharmacy have yet to be investigated thoroughly, 
careful monitoring of these patients and future research on the development of com-
prehensive clinical guidelines for the use of combination therapy are needed.31
At the time of data collection, 14 of the 22 patients (63.6%) were receiving aripip-
razole treatment, resulting in a withdrawal rate of 36.4%. The high withdrawal rate 
may be attributable to the range of dosages used in this study (7.5–40 mg/d); this 
range was broader and higher than that reported in previously published studies in 
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children and adolescents using aripiprazole (5–20 mg/d).10,32,33 In an open-label study 
in 24 children and adolescents with tic disorders in the Republic of Korea, the mean 
dosage was 9.8 mg/d (range, 2.5–20 mg/d).12 Results from a review of the literature 
on the use of antipsychotics in children suggested a lower optimal dosage in children 
than in adults.3 In the present study, 5 patients discontinued aripiprazole treatment 
due to insufficient effect, and the mean (SD) duration of aripiprazole use until discon-
tinuation due to adverse events was 103.3 (84.6) days, suggesting that treatment 
refractoriness may have contributed more to the discontinuation of aripiprazole than 
the adverse events that occurred with use of the drug. 
Adverse events occurred in 14 patients (63.6%) and led to treatment discontinua-
tion in 3 patients (13.6%). This finding is consistent with those from a retrospective 
chart review that reported that 68% of 73 children using antipsychotics experienced 
an adverse drug reaction and that one third discontinued the medication.17 Results 
from an open-label study of the tolerability of aripiprazole in 21 children and adoles-
cents suggested that after forced titration to dosages of 20, 25, and 30 mg/d, 19% of 
the patients discontinued the medication within 1 month due to drug intolerance.9 
Long-term retrospective evaluations of aripiprazole use in 17 children and 32 ado-
lescents have also reported that approximately half of patients experienced adverse 
events at a dose range of 5 to 20 mg, with a 22% to 59% discontinuation rate due to 
adverse events.11,33
In a literature review by Cheng-Shannon et al,3 the most commonly reported ad-
verse events that occurred with aripiprazole use in children were somnolence, vomit-
ing, and increased appetite. A randomized controlled trial of aripiprazole (10 and 
30 mg and placebo) in 302 adolescents with schizophrenia reported tremor (22.8%), 
EPS (17.3%), and somnolence (13.4%) as the most common adverse events.14 Motor 
EPS was the most common adverse event in the present study, and aripiprazole treat-
ment was discontinued in 3 patients due to intolerable events (akathisia [2] and motor 
EPS [1]). Similar rates of motor EPS and akathisia were reported among the children 
and adolescents with tic disorder in the Republic of Korea.12 The results from the 
present study suggested that the age at treatment initiation was not associated with 
treatment response or susceptibility to adverse events. However, the present study 
may have lacked power to detect differences, and larger trials are necessary to confirm 
these findings.
There were several limitations to this study. The retrospective nature inherently 
limited interpretation of the results due to uncontrolled confounders, although the 
findings reflect the conventional use of aripiprazole in the routine clinical setting.2,34 
The patients might have initiated aripiprazole treatment during clinical deterioration 
and might have improved over time regardless of the medication administered. The 
study may also have lacked the power to detect meaningful differences due to its small 
sample size. Due to the retrospective design, there was limited information on adverse 
events, especially metabolic findings (eg, blood glucose and serum lipid concentra-
tions, weight changes). The duration of treatment was heterogeneous because patients 
who used aripiprazole for a short duration and those who used aripiprazole long-term 
were both included to give clinicians information on the entire scope of aripiprazole 
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treatment in children with EOSS. Pharmacotherapy was the main modality of treat-
ment in most of the patients in the present study. However, the stable milieu provided 
by hospitalization and the supportive psychotherapy provided by the treating clini-
cian during outpatient visits may have been therapeutic to the patients. The sample 
size was small due to the rarity and severity of EOSS, and the fact that children are 
still developing poses certain limitations on the validity of the clinical diagnoses.
CONCLUSIONS
Although the retrospective nature of this case series must be taken into account, the 
results suggest that aripiprazole may be an option in the treatment of EOSS in 
children and adolescents. The data suggest that aripiprazole may be more effective in 
reducing negative than positive symptoms.
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